Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roll Over Yamanaka: Meet The Cell Therapy Company Bypassing iPSCs

Mogrify Flips Adult Cells Directly From State To State

Executive Summary

Emerging Company Profile: Horizon Discovery’s former CEO Darrin Disley talks to Scrip about the importance of Mogrify’s revolutionary platform for converting cells into any state without the need to create stem cells and force them through evolutionary biology.

You may also be interested in...



20 Voices: What Does 2024 Hold For Biopharma?

20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC126109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel